Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

MIV-701 begins clinical studies for osteoporosis

March 8, 2007

PHX-1149 significantly improves postprandial glucose and HbA1c levels

March 7, 2007

E1-I.N.T. reduces HbA1c levels in type 1 and type 2 diabetes

March 7, 2007

Phase III studies of ferumoxytol cleared to continue to completion

March 7, 2007

Novel treatment options for metabolic disorders described in recent patents

March 7, 2007

Recent patents describe new therapeutic agents for endocrine-related disorders

March 7, 2007

C1 inhibitor concentrate relieves skin swelling in hereditary angioedema

March 6, 2007

Follistim approved in Japan for new indication

March 5, 2007

Bremelanotide shows activity in postmenopausal women with FSAD

March 5, 2007

Acrux and Organon to develop contraceptive sprays

March 5, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...